Japan · Delayed Price · Currency is JPY MedRx Statistics
Total Valuation
MedRx has a market cap or net worth of JPY 4.94 billion. The enterprise value is 3.27 billion.
| Market Cap | 4.94B |
| Enterprise Value | 3.27B |
Important Dates
The next estimated earnings date is Friday, November 7, 2025.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MedRx has 55.50 million shares outstanding. The number of shares has increased by 23.37% in one year.
| Current Share Class | 55.50M |
| Shares Outstanding | 55.50M |
| Shares Change (YoY) | +23.37% |
| Shares Change (QoQ) | +6.82% |
| Owned by Insiders (%) | 3.82% |
| Owned by Institutions (%) | -4.65% |
| Float | 49.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 112.25 |
| PB Ratio | 2.64 |
| P/TBV Ratio | 2.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.38 |
| EV / Sales | 74.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 28.24
| Current Ratio | 28.24 |
| Quick Ratio | 27.13 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.03% and return on invested capital (ROIC) is -36.32%.
| Return on Equity (ROE) | -63.03% |
| Return on Assets (ROA) | -35.46% |
| Return on Invested Capital (ROIC) | -36.32% |
| Return on Capital Employed (ROCE) | -67.68% |
| Revenue Per Employee | 2.00M |
| Profits Per Employee | -62.45M |
| Employee Count | 22 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.07 |
Taxes
In the past 12 months, MedRx has paid 12.00 million in taxes.
| Income Tax | 12.00M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -7.29% in the last 52 weeks. The beta is 0.71, so MedRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | -7.29% |
| 50-Day Moving Average | 92.30 |
| 200-Day Moving Average | 79.13 |
| Relative Strength Index (RSI) | 41.86 |
| Average Volume (20 Days) | 9,917,550 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedRx had revenue of JPY 44.00 million and -1.37 billion in losses. Loss per share was -28.69.
| Revenue | 44.00M |
| Gross Profit | 43.00M |
| Operating Income | -1.27B |
| Pretax Income | -1.36B |
| Net Income | -1.37B |
| EBITDA | -1.24B |
| EBIT | -1.27B |
| Loss Per Share | -28.69 |
Balance Sheet
The company has 1.67 billion in cash and n/a in debt, giving a net cash position of 1.67 billion or 30.04 per share.
| Cash & Cash Equivalents | 1.67B |
| Total Debt | n/a |
| Net Cash | 1.67B |
| Net Cash Per Share | 30.04 |
| Equity (Book Value) | 1.87B |
| Book Value Per Share | 34.99 |
| Working Capital | 1.69B |
Cash Flow
| Operating Cash Flow | -1.24B |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 97.73% |
| Operating Margin | -2,879.55% |
| Pretax Margin | -3,095.45% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MedRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.37% |
| Shareholder Yield | n/a |
| Earnings Yield | -27.82% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MedRx has an Altman Z-Score of 37.82 and a Piotroski F-Score of 1.
| Altman Z-Score | 37.82 |
| Piotroski F-Score | 1 |